首页> 外国专利> PD-L1 antibody (join a planned human cell death alliance)

PD-L1 antibody (join a planned human cell death alliance)

机译:PD-L1抗体(加入计划中的人类细胞死亡联盟)

摘要

An antibody is added to a planned human cell death Alliance (PD-L1 human) (SEQ ID No.1)It is characterized by a light chain (LC) and a heavy chain (HC),The light chain includes a variable light chain region (LCVR) and a heavy chain includes a variable heavy chain region (hcvr),LCVR consists of LCDR1, LCDR2 and LCDR3 light chain complementary determining regions, including amino acid sgssnigsnitvn sequence (SEQ ID No.5, ygnrps (SEQ ID No.6),And qsydslsgssv (SEQ ID No: 7)Hcvr consists of HCDR1, HCDR2 and HCDR3, which contain the amino acid sequence of kasggtfssyais (SEQ ID No.2),Giipifgtanyaqkfqg (SEQ ID No.3) and arspdyspyyyygmdv (SEQ ID No.4),namely These may be effective methods for the treatment of colon tumors and blood pathology to prevent chemotherapy alone and in combination with other cancer treatments.
机译:将抗体加入计划中的人类细胞死亡联盟(PD-L1人类)(SEQ ID No.1),其特征是轻链(LC)和重链(HC),轻链包括可变轻链区域(LCVR)和重链包括可变重链区域(hcvr),LCVR由LCDR1,LCDR2和LCDR3轻链互补决定区组成,包括氨基酸ssssnigsnitvn序列(SEQ ID No.5,ygnrps(SEQ ID No. 6),qsydslsgssv(SEQ ID No:7)Hcvr由HCDR1,HCDR2和HCDR3组成,其中包含kasggtfssyais(SEQ ID No.2),Giipifgtanyaqkfqg(SEQ ID No.3)和arspdyspyyyygmdv(SEQ ID No.3)的氨基酸序列No.4),即这些可能是治疗结肠肿瘤和血液病理学的有效方法,可以单独预防化疗以及与其他癌症治疗联合使用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号